Omnicell’s third quarter was marked by disciplined operational execution, which the market responded to positively. Management attributed performance to ongoing cost efficiency initiatives and favorable customer and product mix, helping offset flat sales. CEO Randall Lipps pointed to robust engagement with health systems and highlighted the growing importance of automation and enterprise-wide medication management as fundamental to Omnicell’s value proposition. The company also benefited from expanding leasing programs and maintained momentum in its automated dispensing cabinet business, which remains deeply embedded in U.S. acute care settings.
Is now the time to buy OMCL? Find out in our full research report (it’s free for active Edge members).
Omnicell (OMCL) Q3 2026 highlights:
- Revenue $307.9 million vs S&P analysts’ estimates of $305.9 million (flat year on year, 0.6% beat)
- Adjusted EPS $0.58 vs S&P analysts’ estimates of $0.42 (38.9% beat)
- Adjusted EBITDA $44.93 million vs analyst estimates of $36.1 million (14.6% margin, 24.5% beat)
- Revenue guidance $298 million at the midpoint for Q4 2026, below analyst estimates of $311.5 million
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 13.3% increase
- EBITDA guidance $190 million at the midpoint for the full year, above analyst estimates of $181.3 million
- Operating margin 4.9%, up from 2.7% in the same quarter last year
- Market capitalization $1.67 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Omnicell’s Q3 earnings call
-
Stan Berenshteyn (Wells Fargo) asked about the variability in bookings guidance and whether unclosed deals would roll into future periods. CFO Baird Radford explained that timing of large deals is difficult to predict due to customer-driven decision cycles, with potential for carryover into future quarters.
-
Jessica Tassan (Piper Sandler) inquired about the economics and adoption pace of leasing versus purchasing. Radford clarified that while leasing now accounts for a growing share of deals, it brings lower upfront gross margins but recurring revenue and higher aggregate margins over time.
-
Allen Lutz (Bank of America) questioned the contribution of Titan XT to near-term bookings and shifts in product pipeline. President Nnamdi Njoku confirmed that Titan XT shipments had just begun and impact will be more pronounced in 2027 as the refresh accelerates.
-
Talef Corman (Craig-Hallum) asked about subscription lengths for OmniSphere. Njoku said the company is still testing pricing and contract durations, aiming to balance customer flexibility and predictable revenue.
-
David Larsen (BTIG) sought clarity on the incremental revenue opportunity from OmniSphere. Management noted that OmniSphere monetization is incremental to the previously disclosed hardware opportunity, but specific market sizing was not provided.
Catalysts in upcoming quarters
Looking ahead, the StockStory team will be watching (1) the adoption rate and attach rates for OmniSphere among existing and new Titan XT customers, (2) the pace and mix of leasing versus capital sales in the hospital channel, and (3) margin trends as cost pressures from memory components and policy changes unfold. Execution in competitive wins and continued progress in government and specialty pharmacy channels will also be critical signposts.
Omnicell currently trades at $36.67, up from $35.95 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
Our favorite stocks right now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.